These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17449254)

  • 1. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer.
    Fernandes C; Oliveira C; Gano L; Bourkoula A; Pirmettis I; Santos I
    Bioorg Med Chem; 2007 Jun; 15(12):3974-80. PubMed ID: 17449254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
    Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
    Ann Nucl Med; 2011 Feb; 25(2):117-24. PubMed ID: 21058048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
    Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
    Ann Nucl Med; 2012 Jun; 26(5):381-9. PubMed ID: 22354330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
    Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I
    Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.
    Hirata M; Kanai Y; Naka S; Yoshimoto M; Kagawa S; Matsumuro K; Katsuma H; Yamaguchi H; Magata Y; Ohmomo Y
    Ann Nucl Med; 2013 Jun; 27(5):431-43. PubMed ID: 23494210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
    Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
    Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
    Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
    Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
    Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M
    Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging.
    Fernandes C; Santos IC; Santos I; Pietzsch HJ; Kunstler JU; Kraus W; Rey A; Margaritis N; Bourkoula A; Chiotellis A; Paravatou-Petsotas M; Pirmettis I
    Dalton Trans; 2008 Jun; (24):3215-25. PubMed ID: 18688420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging.
    Bourkoula A; Paravatou-Petsotas M; Papadopoulos A; Santos I; Pietzsch HJ; Livaniou E; Pelecanou M; Papadopoulos M; Pirmettis I
    Eur J Med Chem; 2009 Oct; 44(10):4021-7. PubMed ID: 19487055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
    Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
    Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor.
    Dissoki S; Aviv Y; Laky D; Abourbeh G; Levitzki A; Mishani E
    Appl Radiat Isot; 2007 Oct; 65(10):1140-51. PubMed ID: 17574425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA.
    Brahimi F; Rachid Z; Qiu Q; McNamee JP; Li YJ; Tari AM; Jean-Claude BJ
    Int J Cancer; 2004 Nov; 112(3):484-91. PubMed ID: 15382076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: in vitro and docking experiments.
    de Oliveira AN; Bocca CC; Carvalho JE; Ruiz AL; Silva TP; Rittner R; Hoehr NF
    Eur J Med Chem; 2010 Sep; 45(9):4339-42. PubMed ID: 20627376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.